Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Rhea-AI Summary
Can-Fite (NYSE American: CANF) announced the Canadian Patent Office issued a notice of allowance for Canadian Patent Application No. 3,126,002, covering Namodenoson for use as an anti-obesity therapy.
The allowance adds Canadian IP to existing U.S. and Australian obesity/metabolic patents, cites preclinical fat reduction and a MASH Phase IIa observation of 2.3% weight loss after 3 months with increased adiponectin, and highlights an excellent oral safety profile.
Positive
- Canadian patent allowance for Namodenoson (Application No. 3,126,002)
- Existing U.S. and Australian patents for obesity/metabolic uses
- MASH Phase IIa: 2.3% weight loss after 3 months
- Described excellent oral safety profile across multiple studies
Negative
- Clinical obesity evidence limited to one Phase IIa trial and animal model
- Observed weight loss in patients was modest at 2.3% over 3 months
News Market Reaction – CANF
In the Feb 9 session, CANF gained 1.44%, reflecting a mild positive market reaction. Argus tracked a peak move of +16.6% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Clinical case update | Positive | +5.2% | Compassionate-use Namodenoson case enabling successful liver transplantation. |
| Jan 20 | Trial enrollment | Positive | -0.3% | Completion of Phase 2a enrollment in advanced pancreatic cancer study. |
| Dec 26 | Patent grant | Positive | +18.6% | Brazilian patent granted for A3AR agonist in sexual dysfunction. |
| Dec 23 | Corporate action | Negative | -1.7% | 1-for-3,000 reverse split and ADS ratio change implementation details. |
| Dec 16 | Pipeline & financials | Positive | +9.1% | Update on multiple Namodenoson and Piclidenoson trials plus cash position and raises. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical and patent updates have often coincided with positive price reactions, with only one mild divergence on enrollment news.
Over recent months, Can-Fite has reported multiple Namodenoson milestones and IP expansions. A compassionate-use liver cirrhosis case on Feb 5, 2026 and Brazilian sexual dysfunction patent on Dec 26, 2025 were followed by double‑digit gains. A reverse split announcement on Dec 23, 2025 saw a modest decline. The current Canadian anti‑obesity patent allowance extends this pattern of broadening A3 adenosine receptor indications alongside ongoing Phase II and Phase III liver and pancreatic programs.
Key Terms
a3 adenosine receptor medical
agonist medical
phase iia medical
adiponectin medical
compound annual growth rate financial
cagr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market
Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled “An A3 adenosine receptor ligand for use for achieving a fat loss effect.
The patent covers the use of Namodenoson, Can-Fite’s orally bioavailable A3 adenosine receptor (A3AR) agonist, for reducing fat mass and body weight, providing intellectual property protection in Canada for its development as an anti-obesity therapy.
Can-Fite already holds corresponding patents in the United States and Australia for the use of Namodenoson in obesity and metabolic disorders. Namodenoson is currently in clinical development for Metabolic Dysfunction-Associated Steatohepatitis (MASH), advanced liver cancer, and pancreatic cancer, and has demonstrated an excellent safety profile across multiple clinical studies following oral administration.
The anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental animal model of obesity, induced by high fat diet. In a MASH Phase IIa study, in patients treated with Namodenoson, a
“Expanding our intellectual property estate into metabolic indications such as fat loss creates new development and partnering opportunities and reinforces the long-term value of our A3 adenosine receptor platform,” said Pnina Fishman, Ph.D., Can-Fite CSO and Chairperson.
The global obesity treatment market is projected to reach
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), and in a Phase IIa study in pancreatic cancer. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
+972-3-9241114
